News

News-Medical.Net on MSN2d
One RSV shot cuts severe lung infections in older adults for three seasons, trial shows
A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...
McKnight's Long-Term Care News1d
RSV vaccine wanes in older adults over three seasons, trial shows
A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...
Managed Healthcare Executive3d
A Win for Adult RSV Vaccination Amid Vaccine Uncertainty, Hesitancy
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Knowridge Science Report5d
Single-dose RSV vaccine protects older adults across three seasons, global study finds
A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...
Medical Dialogues6d
GSK Arexvy recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices
GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of ...
European Medical Journal5d
Single RSV Vaccine Dose Protects Older Adults Across Three Seasons
A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...
CNA3dOpinion
Commentary: High-profile pneumonia deaths highlight the threat of respiratory infections
Some assume pneumonia is an inevitable consequence of ageing, while others may not realise they are at risk, says infectious ...
Sportschosun on MSN2d
Cha Seung-won picks model for RSV vaccine ALEXB
Cha Seung-won was selected as a model for the Respiratory Synthetic Virus (RSV) vaccine 'AlexB'. GSK Korea announced that it ...
Pharmabiz6d
ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease
voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease ...
MPR1d
ACIP Recommends RSV Vaccine for 50 to 59-Year-Olds at High Risk
Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.